美国 · SEC FORM 4
IONIS PHARMACEUTICALS INC
IONS · Nasdaq · CIK 0000874015 · Healthcare · Biotechnology
内部人信号
2 qualifying P purchase groups
当前 180 天评分窗口
56 同一窗口内观察到的 Form 4 交易行
24 sales · 30 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号?
评分构成
活跃窗口内没有合资格买入,因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数?
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示,不会形成负分。
卖出和其他 Form 4 活动会单独显示,不会形成负面买入信号。没有买入不会被评分为看空。
买方广度与集中度
Roles in the peak window: Director. Concentration uses priced qualifying P lines only and does not change the saved score.
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型;卖出仅作为背景。
Showing the six most active owners; 8 additional owner(s) remain in Form 4 申报证据.
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2026-07-31 · Hayden Michael R.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据,不影响内部人信号。
- 空头股数
- 22,508,744
- 上期报告
- 20,890,252
- 日均成交量
- 4,881,042
- 回补天数
- 4.6
FINRA 结算日:2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数,每月两个结算日之后约一周公布;不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-07-31 | Hayden Michael R | 买入 (P) | Common Stock | 5,000 | USD 51.60 | USD 258,000 | SEC 申报 ↗ |
| 2026-07-30 | Hayden Michael R | 买入 (P) | Common Stock | 15,000 | USD 53.38 | USD 800,700 | SEC 申报 ↗ |
| 2025-05-01 | Hayden Michael R | 买入 (P) | Common Stock | 15,000 | USD 31.86 | USD 477,900 | SEC 申报 ↗ |
| 2024-12-23 | Hayden Michael R | 买入 (P) | Common Stock | 5,000 | USD 36.22 | USD 181,075 | SEC 申报 ↗ |
Form 4 申报证据
239 transaction lines in the latest 365-day window; 923 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-31 | O'NEIL PATRICK R. | J (J) | Common Stock | 63 | USD 51.31 | USD 3,233 | SEC 申报 ↗ |
| 2026-08-31 | Monia Brett P | J (J) | Common Stock | 98 | USD 51.31 | USD 5,028 | SEC 申报 ↗ |
| 2026-08-31 | Birchler Brian | J (J) | Common Stock | 58 | USD 51.31 | USD 2,976 | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-31 | O'NEIL PATRICK R. | J (J) | Common Stock | 63 | USD 51.31 | USD 3,233 | SEC 申报 ↗ |
| 2026-08-31 | Monia Brett P | J (J) | Common Stock | 98 | USD 51.31 | USD 5,028 | SEC 申报 ↗ |
| 2026-08-31 | Birchler Brian | J (J) | Common Stock | 58 | USD 51.31 | USD 2,976 | SEC 申报 ↗ |
| 2026-08-31 | BENNETT C FRANK | J (J) | Common Stock | 110 | USD 51.31 | USD 5,644 | SEC 申报 ↗ |
| 2026-07-31 | Hayden Michael R | 买入 (P) | Common Stock | 5,000 | USD 51.60 | USD 258,000 | SEC 申报 ↗ |
| 2026-07-30 | Hayden Michael R | 买入 (P) | Common Stock | 15,000 | USD 53.38 | USD 800,700 | SEC 申报 ↗ |
| 2026-07-15 | HERMAN JOAN E | 期权行权/转换 (M) | Common Stock | 5,220 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-07-15 | BERTHELSEN SPENCER R | 期权行权/转换 (M) | Common Stock | 5,220 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-07-07 | Kordasiewicz Holly B. | 卖出 (S) | Common Stock | 362 | USD 84.30 | USD 30,517 | SEC 申报 ↗ |
| 2026-07-07 | Diaz Allene M. | 卖出 (S) | Common Stock | 10,111 | USD 85.42 | USD 863,682 | SEC 申报 ↗ |
| 2026-07-07 | Diaz Allene M. | 期权行权/转换 (M) | Common Stock | 10,111 | USD 47.11 | USD 476,329 | SEC 申报 ↗ |
| 2026-07-07 | BENNETT C FRANK | 卖出 (S) | Common Stock | 20,536 | USD 84.95 | USD 1,744,599 | SEC 申报 ↗ |
| 2026-07-07 | BENNETT C FRANK | J (J) | Common Stock | 15,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-07-01 | KLEIN JOSEPH III | 卖出 (S) | Common Stock | 11,518 | USD 79.04 | USD 910,423 | SEC 申报 ↗ |
| 2026-07-01 | KLEIN JOSEPH III | 期权行权/转换 (M) | Common Stock | 11,518 | USD 39.94 | USD 460,029 | SEC 申报 ↗ |
| 2026-06-26 | Schneider Eugene | 卖出 (S) | Common Stock | 26,000 | USD 81.05 | USD 2,107,300 | SEC 申报 ↗ |
| 2026-06-26 | Schneider Eugene | 期权行权/转换 (M) | Common Stock | 26,000 | USD 60.89 | USD 1,583,140 | SEC 申报 ↗ |
| 2026-06-26 | O'NEIL PATRICK R. | 卖出 (S) | Common Stock | 3,069 | USD 80.00 | USD 245,520 | SEC 申报 ↗ |
| 2026-06-26 | Baroldi Joseph | 卖出 (S) | Common Stock | 5,635 | USD 80.16 | USD 451,702 | SEC 申报 ↗ |
| 2026-06-26 | Baroldi Joseph | 期权行权/转换 (M) | Common Stock | 5,635 | USD 49.19 | USD 277,181 | SEC 申报 ↗ |
| 2026-06-26 | Monia Brett P | 卖出 (S) | Common Stock | 50,000 | USD 80.59 | USD 4,029,500 | SEC 申报 ↗ |
| 2026-06-26 | Monia Brett P | 期权行权/转换 (M) | Common Stock | 50,000 | USD 56.78 | USD 2,839,000 | SEC 申报 ↗ |
| 2026-06-25 | Swayze Eric | 卖出 (S) | Common Stock | 10,602 | USD 79.18 | USD 839,466 | SEC 申报 ↗ |
| 2026-06-25 | Monia Brett P | 卖出 (S) | Common Stock | 21,072 | USD 78.49 | USD 1,653,941 | SEC 申报 ↗ |
| 2026-06-25 | Monia Brett P | 期权行权/转换 (M) | Common Stock | 21,072 | USD 32.60 | USD 686,947 | SEC 申报 ↗ |
| 2026-06-24 | Monia Brett P | 卖出 (S) | Common Stock | 14,565 | USD 78.41 | USD 1,142,042 | SEC 申报 ↗ |
| 2026-06-24 | Monia Brett P | 期权行权/转换 (M) | Common Stock | 14,565 | USD 32.60 | USD 474,819 | SEC 申报 ↗ |
| 2026-06-15 | BERTHELSEN SPENCER R | 卖出 (S) | Common Stock | 8,000 | USD 73.49 | USD 587,920 | SEC 申报 ↗ |
| 2026-06-15 | BERTHELSEN SPENCER R | 期权行权/转换 (M) | Common Stock | 8,000 | USD 24.42 | USD 195,360 | SEC 申报 ↗ |
| 2026-06-12 | Kordasiewicz Holly B. | 卖出 (S) | Common Stock | 60,846 | USD 73.40 | USD 4,466,282 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-19 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | IONS |
| CIK | 0000874015 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 923 transaction lines from 2020-01-02 to 2026-08-31 5 P purchase lines · 387 S sale lines · 531 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.